Research
Hormonal
Bariatric surgery does not provide superior long-term cardiovascular benefits (specifically blood pressure and cholesterol) compared to non-surgical treatments.
While surgery is excellent for weight and diabetes, do not assume it automatically fixes heart health long-term. Monitor blood pressure and cholesterol closely, as non-surgical management may sometimes match or exceed surgical benefits in these specific areas over many years.
GoodRefutesMEDIUM confidence
along with the increasing follow-up period, the cardiovascular improvement has been therapeutically offset among patients undergoing bariatric surgery... distant benefits of cardiovascular disorders remain controversial
Why this rating
Meta-analysis data, though heterogeneity exists.
Source
The comprehensive summary of surgical versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomized controlled trials
Ji Cheng et al. · Oncotarget · 2016
DOI 10.18632/oncotarget.9581
Meta-analysis · 25 studiesCited 84×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →